Defining Optimal Health Range for Thyroid Function Based on the Risk of Cardiovascular Disease. by Chaker, L. et al.
   
 
 
 
 
Serveur Acade´mique Lausannois SERVAL serval.unil.ch
Author Manuscript
Faculty of Biology and Medicine Publication
This paper has been peer-reviewed but does not include the final publisher
proof-corrections or journal pagination.
Published in final edited form as:
Title: Defining Optimal Health Range for Thyroid Function Based on the
Risk of Cardiovascular Disease.
Authors: Chaker L, Korevaar TIM, Rizopoulos D, Collet TH, Vo¨lzke H,
Hofman A, Rodondi N, Cappola AR, Peeters RP, Franco OH
Journal: The Journal of clinical endocrinology and metabolism
Year: 2017 Aug 1
Issue: 102
Volume: 8
Pages: 2853-2861
DOI: 10.1210/jc.2017-00410
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.
	1	
	
Defining optimal health range for thyroid function based on 1	
the risk of cardiovascular disease 2	
 3	
L. Chaker1,2,3, T.I.M. Korevaar1,2,3,  D. Rizopoulos4, T-H Collet5, H. Völzke6, A. Hofman3,7, N  Rodondi8,9, 4	
A.R. Cappola10, R.P. Peeters1,2,3, O.H. Franco3 5	
1Rotterdam Thyroid Center, 2Department of Internal Medicine 3Department of Epidemiology and, 6	
4Department of Biostatistics, Erasmus University Medical Center,  5Service of Endocrinology, Diabetes 7	
and Metabolism, University Hospital of Lausanne, Lausanne, Switzerland  6Institute for Community 8	
Medicine, Clinical-Epidemiological Research/SHIP, University Medicine, Greifswald and German Centre 9	
of Cardiovascular Research, Partner Site Greifswald, Germany  7Department of Epidemiology, Harvard 10	
T.H. Chan School of Public Health, Boston, Massachusetts, USA 8Department of General Internal 11	
Medicine, Inselspital, Bern University Hospital and  9Institute of Primary Health Care (BIHAM), University 12	
of Bern, Switzerland. 10Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, 13	
School of Medicine, University of Pennsylvania, Philadelphia, USA 14	
Corresponding author 15	
R.P. Peeters MD, PhD,  16	
Department of Internal Medicine and Rotterdam Thyroid Center,  17	
Erasmus University Medical Center,  18	
Room Ee 500, PO Box 2040, 3000 CA Rotterdam, The Netherlands, 19	
Tel: +31-10-7043363; Fax: +31-10-7035430, Email: r.peeters@erasmusmc.nl 20	
 21	
Short Title: Defining optimal health range for thyroid function, Chaker et al. 22	
Abstract 247, Word Count 3106, Tables: 4+ 1 supplemental, Figures: 1 + 1 Supplemental 23	
Disclosure: The author reports no conflicts of interest in this work.  24	
	2	
	
Abstract 25	
Context: Reference ranges of thyroid stimulating hormone (TSH) and free thyroxine (FT4) are defined by 26	
their distribution in apparently healthy populations, (2.5th and 97.5th percentiles) irrespective of disease 27	
risk and used as cut-offs for defining and clinically managing thyroid dysfunction.  28	
Objective: To provide a proof of concept in defining thyroid function optimal health ranges based on 29	
cardiovascular disease (CVD) mortality risk. 30	
Design and Participants: 9,233 participants from the Rotterdam Study (mean age 65.0 years) were 31	
followed up (median 8.8 years) from baseline to date of death or end of follow-up (2012), which ever 32	
came first (689 cases of CVD mortality). 33	
Main Outcomes: We calculated 10-year absolute risks of CVD mortality (defined according to SCORE 34	
project) using a Fine and Grey competing risk model per percentile of TSH and FT4, modelled non-35	
linearly and sex- and age-adjusted.  36	
Results: Overall, FT4 > 90th percentile was associated with a predicted 10-year CVD mortality risk >7.5% 37	
(p =0.005). In men, FT4 > 97th percentile was associated with a risk of 10.8% (p<0.001). In participants ≥ 38	
65 years, absolute risk estimates were <10.0% below the 30th percentile (~14.5 pmol/L or 1.10 ng/dL) and 39	
≥15.0% above the 97th percentile of FT4 (~22 pmol/L or 1.70 ng/dL).  40	
Conclusions: We describe absolute 10-year CVD mortality risks according to thyroid function (TSH and 41	
FT4) and suggest optimal health ranges for thyroid function can be defined according to disease risk and 42	
are possibly sex and age-dependent. These results need to be replicated with sufficient samples and 43	
representative populations. 44	
Keywords: thyroid function, optimal health range, reference range, cardiovascular disease   45	
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1. Introduction 46	
Reference ranges of blood and other clinical tests are predominantly statistically defined using the 2.5th 47	
and 97.5th percentile interval of the population distribution in an apparently healthy population. These 48	
reference ranges are typically established under the assumption of a normal distribution or a log-normal 49	
distribution and are therefore also referred to as “normal ranges”. This definition of a reference range 50	
does not account for whether individuals are symptomatic or at risk of potential adverse events or 51	
disease. Nevertheless, these biochemically defined reference values are frequently used to define 52	
sickness and health in clinical practice ignoring the inherent risk of the population.   53	
The reference ranges of thyroid function tests, defined by thyroid stimulating hormone (TSH) and free 54	
thyroxine (FT4), are examples of reference ranges defined by their distribution. TSh and FT4 reference 55	
ranges are currently used as cut-offs to define subclinical and overt thyroid disease, and guide treatment 56	
decisions. However, accumulating evidence suggests that subclinical thyroid dysfunction, defined by TSH 57	
outside of the reference range but FT4 within the reference range, is also associated with various clinical 58	
adverse outcomes, including coronary heart disease (CHD) and cardiovascular mortality, at the 59	
extremes.(1,2) Moreover, even differences in thyroid function within the defined reference range are 60	
associated with differing risk of cardiovascular events including atrial fibrillation, stroke, sudden cardiac 61	
death and cardiovascular mortality.(3-7) Based on the increased risk of CHD in subclinical 62	
hypothyroidism, current guidelines advocate treatment with levothyroxine above a TSH of 10 mIU/L, 63	
independent of FT4.(8) Extending this concept, the re-evaluation of thyroid function ranges could take 64	
clinical adverse events into account and thus move from reference ranges towards “optimal health 65	
ranges” for thyroid function. 66	
This approach has been successfully applied to management of myocardial infarction, stroke and 67	
diabetes using cholesterol, blood pressure or glucose measurements.(9) For example, the defined range 68	
for total cholesterol does not rely on the distribution of total cholesterol in a specific population, but rather 69	
on the associated 10-year risk of cardiovascular mortality.(9) Pursuing the same strategy for thyroid 70	
function might not be as straightforward as for other biomarkers. The risk of adverse events is relevant for 71	
both high and low thyroid function, suggesting a non-linear association, in contrast to cholesterol for 72	
example, where the focus is on the high end of the measurement. Furthermore, thyroid dysfunction is not 73	
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solely associated with cardiovascular disease (CVD), but has important implications for bone health and 74	
possibly also cognitive health. (10-13) 75	
We therefore aimed to calculate the 10-year absolute risk of cardiovascular mortality in a large 76	
population-based cohort study by the two most commonly used parameters of thyroid function, TSH and 77	
FT4. We further aimed to define optimal health ranges based on provided absolute risk estimates in the 78	
whole cohort as well as by sex and age groups.  79	
 80	
2. Subjects and Methods 81	
A. The Rotterdam Study 82	
The Rotterdam Study is a prospective population-based cohort study that investigates determinants and 83	
occurrence of age-related diseases in a middle-aged and elderly population in Rotterdam, the 84	
Netherlands. The aims and design of the Rotterdam Study have been described in detail elsewhere.(14) 85	
The Rotterdam Study consists of three independent cohorts: RS Cohort 1 (RSI), including 7,983 86	
participants aged ≥55 (baseline 1990-1993), RS Cohort II (RSII), including 3,011 participants aged ≥55 87	
(baseline 2000-2001) and RS Cohort 3 (RSIII), including 3,932 participants aged ≥45 (baseline 2006-88	
2008). The Rotterdam Study has been approved by the medical ethics committee according to the 89	
Population Screening Act: Rotterdam Study, executed by the Ministry of Health, Welfare and Sports of 90	
the Netherlands.  91	
B. Study population 92	
We selected data from participants from the third visit of the first cohort (1997-1999, n=4797) and the first 93	
visits of the second (2000-2001, n=3011) and third cohort (2006-2008, n=3932), if TSH or FT4 94	
measurements were performed and participants were not using thyroid function altering medication, 95	
including levothyroxine, anti-thyroid drugs, amiodarone or corticosteroids. We did not use the first visit of 96	
the first cohort as thyroid function was measured with a different assay. All participants in the present 97	
analysis provided written informed consent to participate and to obtain information from their treating 98	
physician. All study participants were followed up from the day of baseline laboratory testing to date of 99	
death or end of follow-up January 1, 2012 which ever came first. 100	
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C. Assessment of thyroid function and other baseline measurements 101	
TSH and FT4 measurements were performed using the same methods and assay in blood samples 102	
collected between 1997 and 2008, depending on the cohort and stored at -80°C 103	
(electrochemiluminescence immunoassay for free thyroxine and thyrotropin, “ECLIA”, Roche). Body mass 104	
index was calculated as body mass (kg) divided by the square of the body height (m). Serum cholesterol 105	
was measured using standard laboratory techniques. Systolic blood pressure was calculated as the 106	
average of two consecutive measurements. Over 95% of participants were in fasting state when blood 107	
was drawn (morning) at the Rotterdam Study center visit. Information on tobacco smoking was derived 108	
from baseline questionnaires. Information on medication use was obtained from questionnaires in 109	
combination with pharmacy records. Thyroid medication at baseline and during follow-up, including 110	
thyroid hormone replacement therapy, was prescribed by participant’s own general practitioners (GP) or 111	
specialist and within the context of regular treatment and blinded to measurements of the Rotterdam 112	
Study. 113	
D. Outcome definition 114	
As primary outcome of interest we selected CVD since it is a leading burden of disease, morbidity and 115	
mortality.(15) Additionally, the association of subclinical and overt thyroid dysfunction with CVD mortality 116	
are well-established.(1) Secondary outcomes of interest were CHD and stroke (fatal and non-fatal). 117	
Methods for collection of data and outcome definitions have been previously described .(14,16,17) 118	
Information on the vital status of all participants was obtained on a weekly basis from the central registry 119	
of the municipality in Rotterdam and through digital linkage with records from GPs working in the study 120	
area. The cause of death was established by abstracting information from the medical records of the 121	
general practitioners or nursing home physicians and hospital discharge letters. Cardiovascular mortality 122	
was defined as according to the SCORE project definition of fatal CVD including the ICD-10 codes I10-123	
25, I44-51, I61-73, and R96.(9,18) To test the robustness of our findings we repeated the absolute risk 124	
estimate calculations using the CVD mortality defined according to previously published definition of the 125	
Rotterdam Study, which also included non-atherosclerotic cardiovascular mortality.(16) CHD was defined 126	
as myocardial infarction, cardiac revascularization procedure or CHD mortality. Stroke was defined 127	
according to World Health Organization (WHO) criteria as a syndrome of rapidly developing clinical signs 128	
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of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours or longer or leading to 129	
death, with no apparent cause other than of vascular origin, including ischemic or hemorrhagic strokes. 130	
Outcomes were adjudicated by a committee who were blinded to lab results. 131	
Statistical analyses 132	
Absolute values of TSH and FT4 are assay dependent, but the different immunoassays of TSH or FT4 133	
correlate well in non-pregnant adult populations(19,20), as previously also shown in the Rotterdam 134	
Study.(21) Therefore, to enhance generalizability of our results, we analyzed the association of TSH or 135	
FT4 in percentiles with the outcomes defined below. Absolute 10-year risk estimates of CVD mortality 136	
used the percentiles of TSH and FT4 and were calculated according to the Fine and Gray model, taking 137	
the competing risk of non-CVD deaths into account and were adjusted for age and sex.(22) The 138	
competing risk for the CHD and stroke analyses were non-CHD and non-stroke deaths respectively. In 139	
addition, we performed predefined analyses stratifying for age categories and gender. We performed 140	
sensitivity analyses using a Rotterdam Study based definition for CVD mortality(16), additionally adjusting 141	
the TSH analyses for FT4 and vice versa as well as additionally adjusting the analyses for cardiovascular 142	
risk factors used in the SCORE project charts (i.e. smoking, systolic blood pressure, and cholesterol).(9) 143	
We used the following cut-offs for the risk estimates and color denomination of risk categories, which 144	
were slightly adjusted from the SCORE project due to the higher average age in our population: low risk 145	
(< 2.0%, blue), low-intermediate risk (2.0-5.0%, green), intermediate risk (5.0-7.5%, yellow), high-146	
intermediate risk (7.5-10.0%, orange) and high risk (≥ 10.0%, red). 147	
For the CHD analyses we excluded all those with prevalent or missing information on CHD at baseline 148	
(n=685). For the stroke analyses we excluded all participants with missing information at baseline or a 149	
history of stroke (n=319). We performed a goodness-of-fit test for the Fine and Gray model for the 150	
absolute risk estimations, using the Zou Laird Fine test, and this revealed no linear, quadratic or log time 151	
varying effects of TSH or FT4 (p-value > 0.1 for all analyses). Linearity of absolute risk estimates was 152	
tested with restricted cubic splines with 3 knots at the 10th, 50th and 90th percentile. Analyses were 153	
performed in R (survival, rms, crrSC and cmprsk packages R-project, Institute for Statistics and 154	
Mathematics, R Core Team (2013), Vienna, Austria, version 3.0.2). 155	
 156	
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3. Results 157	
We included a total of 9,233 participants with a mean age of 65.0 (standard deviation 9.8) years of which 158	
55.9% were female (Table 1). During an average follow-up of 8.8 years, with a total of 75,981 person-159	
years, 2166 deaths occurred of which 689 were CVD deaths according to the SCORE criteria and 692 160	
according to the Rotterdam Study criteria. There were 642 CHD events and 553 stroke events during 161	
follow-up. Completeness of follow-up was 99.6%.(23) 162	
Absolute risk estimates cardiovascular mortality 163	
Ten-year absolute risk estimates for CVD mortality across the range of TSH and FT4 are plotted in 164	
Figure 1. CVD mortality increased with higher FT4 levels (p-value 0.005) and lower TSH levels, although 165	
not statistically significantly for the latter. The best fit for both TSH and FT4 analyses was non-linear (p for 166	
non-linearity < 0.001, Figure 1). Table 2 shows the different percentile cut-offs of TSH and FT4 values 167	
with the predicted absolute 10-year risk estimates, based on the non-linear association. Overall, FT4 168	
values above the 97th percentile (absolute level of approximately 22 pmol/L or 1.7 ng/dL) were associated 169	
with a predicted 10-year risk of 9.6% (p-value = 0.005). FT4 levels above the 90th percentile 170	
corresponded to an increased risk of 7.5% and higher for CVD mortality (absolute level of approximately 171	
19 pmol/L or 1.5 ng/dL). Sensitivity analyses additionally adjusting for cardiovascular risk factors, using 172	
the RS definition of CVD mortality or adjusting the TSH analyses for FT4 and vice versa did not change 173	
the definition of the cut-offs meaningfully (Supplemental Table 1). TSH levels were inversely associated 174	
with CVD mortality but not statistically significant (Table 1). 175	
 For men, a risk of ≥10.0% occurred at the 97th percentile of FT4 (p-value < 0.001) and a risk of ≥7.5% 176	
already occurred at the 60th percentile (Table 3). In women, there was no association of the thyroid 177	
function markers and risk of CVD mortality (Table 3). In participants younger than 65 years of age, the 178	
risk of CVD mortality increased with decreasing TSH levels (p-value = 0.009) with a risk of ≥ 2.0 % from 179	
the 30th percentile and lower (~1.40 mIU/L), while FT4 levels were not association with CVD mortality 180	
(Table 4). In participants older than 65 years of age (Table 4), the absolute risk estimates were <10.0% 181	
below the 30th percentile and ≥ 15.0% higher than the 97th percentile of FT4. 182	
Absolute risk estimates CHD and stroke 183	
Supplemental Figure1 plots the absolute risk estimates of CHD and stroke against the continuous FT4 184	
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and TSH levels. In the Fine and Grey models, the association of TSH or FT4 with CHD events was not 185	
statistically significant (p-value > 0.5). Higher FT4 levels were associated with an increased risk of stroke 186	
(p-value = 0.009). TSH levels were inversely associated with the risk of stroke, but this did not reach 187	
statistical significance. The best fit for the CHD analyses was linear, while the best fit for the stroke 188	
analyses was non-linear (p for non-linearity <0.001, Supplemental Figure 1).  189	
 190	
4. Discussion 191	
This is the first study to propose reference ranges of TSH and FT4 to be based upon the disease risk (i.e. 192	
absolute risk estimates of CVD) as a proof of concept. Based on our findings, the proposed upper limit for 193	
FT4 could be the 90th percentile, independent of TSH levels. The optimal health ranges for thyroid 194	
function based on cardiovascular disease seem to differ between men and women and the associations 195	
were not statistically significant in women. In participants older than 65 years of age, the absolute risk 196	
estimates of CVD were <10.0% below the 30th percentile (~14.5 pmol/L or 1.1 ng/dL) and ≥ 15.0% higher 197	
than the 97th percentile of FT4 (~22 pmol/L or 1.7 ng/dL). The associations of TSH and FT4 with CVD 198	
mortality were non-linear. The association of thyroid function with stroke followed a similar pattern, but the 199	
association with CHD showed a linear association. 200	
Reference ranges for the thyroid function biomarkers TSH and FT4 have been derived mainly statistically 201	
from the 2.5th and 97.5th percentile, similar to reference ranges of other laboratory results and clinical 202	
tests.(24-26) Subclinical and overt thyroid disease are subsequently defined by these biochemical and 203	
statistical reference ranges which, in general, do not take future health and disease risks into account. 204	
However, some guidelines do uphold additional cutoffs for treatment based on studies showing an 205	
increased risk of cardiovascular disease at certain levels.(8,27) For example, the European Thyroid 206	
Association guidelines on subclinical hypothyroidism(8), make a distinct separation between TSH levels 207	
below and above 10 mIU/L for consideration of levothyroxine treatment. These recommendations are 208	
based on a study by the Thyroid Studies Collaboration that provided evidence for a higher relative risk of 209	
CHD with TSH levels higher than 10 mIU/L.(1) However, to our knowledge, there are no studies 210	
specifically addressing the optimal health ranges based on absolute risk estimates of adverse health 211	
outcomes.  212	
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Overall, our study shows an absolute 10-year risk of 7.5% or higher with FT4 levels above the 90th 213	
percentile, corresponding to a cut-off level of FT4 approximately 19 pmol/L (~1.5 ng/dL). This is however, 214	
as expected, different in participants younger than 65 years of age compared to those older than 65 215	
years. Also, there seems to be a differential association of thyroid function with absolute risk of CVD 216	
when comparing men to women. Even though this can, at least partially, be attributable to the difference 217	
in background absolute risk between the two sexes, there also seems to be a thyroid dependent 218	
differential risk when comparing men to women. These findings need to be confirmed and validated 219	
across different populations, but could suggest a sex-specific reference range is needed. 220	
In our study, higher FT4 levels are associated with an increased risk of CVD mortality whereas TSH 221	
levels showed an expected opposite relation with CVD mortality which did not reach statistical 222	
significance. The current study is not the first to report an association of FT4 with clinical events, while the 223	
association is lower or absent with TSH.(3,6,21) Based on the log-linear relationship between TSH and 224	
FT4, TSH is perceived as the most sensitive marker in subjects with thyroid disease. The lack of 225	
association with TSH is therefore remarkable. One explanation could be that in euthyroid subjects, TSH 226	
predominantly reflects the pituitary-thyroid axis set point rather than disease risk,(28) while, independent 227	
of TSH, circulating FT4 (and subsequently FT3 acting intracellular) represents the bioavailable thyroid 228	
hormone that can be taken up by cells, thereby leading to clinical consequences of thyroid hormones 229	
peripherally.  230	
There are several strengths to our study including the population-based design, the large size of the study 231	
population, the completeness of follow-up and the fact that outcomes were defined independently from 232	
baseline thyroid function. Nevertheless, the currently proposed optimal health ranges should be 233	
interpreted with caution. First of all, even though CVD is one of the most important clinical outcomes, the 234	
presented absolute risk estimates are solely based on cardiovascular mortality and our findings as such 235	
should be considered as a proof of concept. Furthermore, The Netherlands is classified as a low 236	
cardiovascular mortality risk country by the European Society of Cardiology and therefore estimates are 237	
not generalizable to countries with higher CVD mortality risk.(29) The Rotterdam Study consists of 238	
participants of 45 years and older and mainly Caucasians with, on average, a sufficient iodine 239	
status.(30,31) Also, only one baseline measurement of thyroid function was available and therefore 240	
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changes in thyroid function could not be taken into account. The absolute levels of TSH and FT4 depend 241	
on the assay used and are therefore variable. We therefore used the percentiles of the measurements to 242	
study the associations and define the optimal health ranges, because of the strong correlation between 243	
the different assays of TSH or FT4. These results are potentially better generalizable to other populations. 244	
This is also the reason to advice that the calculation of these percentiles is country, iodine status, region 245	
and if possible even laboratory specific. 246	
The mentioned limitations of our study also highlight the need for further research. Therefore our 247	
approach to define thyroid function adequacy focused on cardiovascular mortality need to be confirmed in 248	
similar populations but also replicated in complementary populations such as younger participants, other 249	
ethnicities and in regions with different current and historical iodine status.(32) Cardiovascular disease is 250	
an established and well-studied outcome in relation to thyroid function. However, recently, there is 251	
increasing interest in the association of thyroid function with other outcomes as well, such as cognition. 252	
Therefore, importantly, consensus is needed on which clinical outcomes are or could be relevant in 253	
defining the optimal health ranges for thyroid function, beyond cardiovascular disease. Lastly, and beyond 254	
the discussion on thyroid function optimal health ranges, consensus is also needed on which 255	
cardiovascular risk is considered too high and whether this is similar for all populations. For example, a 256	
10-year absolute risk of 2.5% for CVD mortality for a person of 45 years of age might not be deemed 257	
equally acceptable compared to the same risk in a person of 75 years. 258	
This is a population-based study, and therefore risks and benefits of treatment decisions were not 259	
explored. While randomized controlled trials are the best evidence for defining treatment cut-offs, they are 260	
costly and not always able to address the timeliest issues. In the absence of results from such trials in the 261	
near future, defining the optimal health ranges by determining the absolute risk estimates of disease, in 262	
various observational studies from representative populations, is perhaps the most feasible.  263	
In summary, we propose an approach to define thyroid function based not only on population’s 264	
distribution but taking into account health and disease risk. We describe the absolute 10-year risk of 265	
cardiovascular mortality associated with TSH and FT4 and provide an example of defining optimal health 266	
ranges based on cardiovascular mortality risk using data from a large population-based study. Further 267	
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research is needed to investigate optimal health ranges based on thyroid-relevant clinical outcomes in 268	
sufficiently powered studies with representative samples from multiple populations.  269	
 270	
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Figure legend 423	
 424	
Figure 1 425	
Absolute 10-year risk of CVD mortality by TSH and FT4  426	
 427	
Absolute 10-years risks of CVD mortality were calculated taking competing risk of death by other causes 428	
into account, and are plotted against TSH and FT4 percentiles and absolute values, with 95% confidence 429	
intervals. P for non-linearity < 0.001 for both TSH and FT4 analyses.  430	
Abbreviations:  CVD cardiovascular disease FT4 free thyroxine, TSH thyroid-stimulating hormone. 431	
  432	
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Table 1: Baseline characteristics of included participants in the Rotterdam Study with TSH or 
FT4 measurements and no thyroid function altering medication 
Variable Mean (SD)a 
Number of participants 9233 
Age, years 65.0 (9.8) 
Female, N (%) 5157 (55.9) 
History of diabetes, N (%) 1097 (11.9) 
BMI kg/m2 27.2 (4.2) 
Cholesterol mmol/L 5.7 (1.0) 
Smoking, N (%)  
   current 1975 (21.4) 
   past 4380 (47.4) 
   never 2878 (31.2) 
Systolic BP, mmHg 139.5 (21.0) 
TSH ImU/L median (IQR) 1.90 (1.29-2.74) 
FT4 pmol/L 15.6 (2.2) 
FT4 ng/dL 1.21 (0.2) 
a Values are means and SD unless otherwise specified 
Abbreviations: BMI = body-mass index; BP = blood pressure; FT4 = free thyroxine; IQR = inter-quartile 
range; N= number; SD = standard deviation; TSH = thyroid-stimulating hormone 
 434	
  435	
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Table 2: Absolute 10-year risk estimates for CVD mortality according to percentiles of TSH and FT4 (n= 9227)* 
Predicted 10-year absolute risk of event (n= 689 cases) 
TSH, percentile  <2nd 2-5th 5-10th 10-20th 20-30th 30-40th 40-50th 50-60th 60-70th 70-80th 80-90th 90-95th 95-97th >97th P-trend   
Absolute risk 
estimates 8.3% 8.3% 7.4% 6.9% 6.5% 5.9% 6.0% 5.5% 5.5% 5.4% 5.3% 6.0% 5.5% 6.0% 0.59 
N 149 164 471 944 959 952 930 958 944 953 933 444 257 169  
Mean TSH 0.03 0.19 0.53 0.97 1.26 1.52 1.76 2.04 2.36 2.77 3.45 4.54 5.74 13.53  
                
FT4 percentiles <2nd 2-5th 5-10th 10-20th 20-30th 30-40th 40-50th 50-60th 60-70th 70-80th 80-90th 90-95th 95-97th >97th P-trend 
Absolute risk 
estimates 4.5% 4.4% 5.1% 4.7% 4.7% 5.2% 5.8% 6.0% 6.2% 6.9% 7.5% 8.4% 8.9% 9.6% 0.005 
N 185 190 476 941 952 961 940 953 939 947 911 463 238 131  
Mean FT4 pmol/L 8.93 11.57 12.57 13.46 14.16 14.73 15.27 15.80 16.36 17.01 17.83 18.85 19.82 22.01  
Mean FT4 ng/dL 0.69 0.90 1.00 1.05 1.10 1.14 1.19 1.23 1.27 1.32 1.39 1.46 1.54 1.71  
                
Models are adjusted for age and sex and computed using a competing risk model. Risk legend: low risk (< 2.0% , blue), low-intermediate risk (2.0-5.0%, green), intermediate 
(5.0-7.5%, yellow), high-intermediate risk (7.5-10.0%, orange), high risk (≥ 10.0%, red) 
Abbreviations: CVD = cardiovascular disease; FT4 = free thyroxine; N = number; TSH = thyroid stimulating hormone 
* 6 people excluded due to missing cause of death 
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Table 3: Absolute 10-year risk estimates for CVD mortality according to percentiles of TSH and FT4 (n= 9227)* 
Predicted 10-year absolute risk of event (n= 689) 
Men,  
N= 4072 cases = 357 
              
TSH, percentile  <2nd 2-5th 5-10th 10-20th 20-30th 30-40th 40-50th 50-60th 60-70th 70-80th 80-90th 90-95th 95-97th >97th P-trend 
Absolute risk 
estimates 11.4% 8.6% 8.8% 8.0% 7.1% 7.0% 7.3% 6.4% 6.6% 6.4% 6.4% 7.8% 7.2% 7.1% 0.46 
N 44 78 216 461 461 472 452 450 408 418 354 159 60 39  
                
FT4 percentiles <2nd 2-5th 5-10th 10-20th 20-30th 30-40th 40-50th 50-60th 60-70th 70-80th 80-90th 90-95th 95-97th >97th P-trend 
Absolute risk 
estimates 4.4% 5.3% 6.1% 5.4% 5.5% 6.1% 6.8% 7.5% 7.6% 8.3% 8.4% 9.0% 9.0% 10.8% <0.001 
N 62 51 199 377 352 412 393 450 425 461 458 244 128 60  
                
Women,  
N = 5155, cases = 332 
              
TSH, percentile  <2nd 2-5th 5-10th 10-20th 20-30th 30-40th 40-50th 50-60th 60-70th 70-80th 80-90th 90-95th 95-97th >97th P-trend 
Absolute risk 
estimates 7.0% 8.1% 6.3% 5.9% 5.9% 4.7% 4.6% 4.7% 4.6% 4.5% 4.6% 5.0% 5.1% 5.9% 0.99 
N 105 86 255 483 498 480 478 508 536 535 579 285 197 130  
                
FT4 percentiles <2nd 2-5th 5-10th 10-20th 20-30th 30-40th 40-50th 50-60th 60-70th 70-80th 80-90th 90-95th 95-97th >97th P-trend 
Absolute risk 
estimates 4.8% 4.3% 4.2% 4.2% 4.3% 4.5% 5.0% 4.7% 5.1% 5.6% 6.7% 7.8% 8.8% 8.6% 0.27 
N 123 139 277 564 600 549 547 503 514 486 453 219 110 71  
                
Models are adjusted for age and sex and computed using a competing risk model.  Risk legend: low risk (< 2.0% , blue), low-intermediate risk (2.0-5.0%, green), intermediate 
(5.0-7.5%, yellow), high-intermediate risk (7.5-10.0%, orange), high risk (≥ 10.0%, red) 
Abbreviations: CVD = cardiovascular disease; FT4 = free thyroxine; N = number; TSH = thyroid stimulating hormone 
* 6 people excluded due to missing cause of death 
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Table 4: Absolute 10-year risk estimates for CVD mortality according to percentiles of TSH and FT4 (n= 9227)* 
Predicted 10-year absolute risk of event (n= 689) 
Age < 65 years,  
N= 5172 cases = 82 
              
TSH, percentile  <2nd 2-5th 5-10th 10-20th 20-30th 30-40th 40-50th 50-60th 60-70th 70-80th 80-90th 90-95th 95-97th >97th P-trend   
Absolute risk 
estimates 2.6% 3.0% 2.6% 2.4% 2.2% 1.9% 1.7% 1.4% 1.3% 1.2% 1.0% 0.9% 0.8% 0.9% 0.009 
N 56 59 234 490 523 557 532 573 564 580 554 233 134 83  
                
FT4 percentiles <2nd 2-5th 5-10th 10-20th 20-30th 30-40th 40-50th 50-60th 60-70th 70-80th 80-90th 90-95th 95-97th >97th P-trend  
Absolute risk 
estimates 1.2% 1.1% 1.3% 1.3% 1.3% 1.5% 1.5% 1.8% 1.8% 1.9% 2.1% 2.2% 2.4% 2.4% 0.20 
N  96 97 285 565 556 561 516 526 508 535 512 239 115 61  
                
Age ≥ 65 years,  
N = 4055, cases = 607 
              
TSH, percentile  <2nd 2-5th 5-10th 10-20th 20-30th 30-40th 40-50th 50-60th 60-70th 70-80th 80-90th 90-95th 95-97th >97th P-trend 
Absolute risk 
estimates 11.8% 11.5% 12.2% 11.9% 11.5% 11.3% 11.2% 11.1% 11.1% 11.2% 10.9% 11.4% 10.5% 10.8% 0.76 
N 93 105 237 454 436 395 398 385 380 373 379 211 123 86  
                
FT4 percentiles <2nd 2-5th 5-10th 10-20th 20-30th 30-40th 40-50th 50-60th 60-70th 70-80th 80-90th 90-95th 95-97th >97th P-trend 
Absolute risk 
estimates 8.1% 7.9% 10.2% 9.3% 9.2% 10.2% 10.7% 11.1% 11.4% 13.1% 14.1% 14.7% 14.9% 15.7% 0.005 
N  89 93 191 376 396 400 424 427 431 412 399 224 123 70  
                
Models are adjusted for age and sex and computed using a competing risk model.  Risk legend: low risk (< 2.0% , blue), low-intermediate risk (2.0-5.0%, green), intermediate 
(5.0-7.5%, yellow), high-intermediate risk (7.5-10.0%, orange), high risk (≥ 10.0%, red) 
Abbreviations: CVD = cardiovascular disease; FT4 = free thyroxine; N = number; TSH = thyroid stimulating hormone 
* 6 people excluded due to missing cause of death 
